Surgical Myomectomy Followed by Oral Myfembree Versus Standard of Care Trial (SOUL)
Status:
Not yet recruiting
Trial end date:
2026-04-01
Target enrollment:
Participant gender:
Summary
In this project, the proposition is that the use of daily dosed Myfembree ( a combination of
relugolix with estradiol and norethindrone acetate), FDA-approved medication to treat heavy
menses fibroid-related symptoms, has the potential to delay the recurrence of fibroid
symptoms, prolong the improved quality of life and delay the need for re-intervention after
uterine sparing surgery versus the routine standard of care.